The United Kingdom and the United States have forged a important bilateral deal that will keep zero import taxes on British medicine products being sold in the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on medicines through the NHS. This move secures that duties on these vital exports will be held at nothing for a duration of the next three years.
This deal comes after earlier threats to significantly raise tariffs on branded drug products, with potential rates discussed as high as 100%.
"This agreement with the UK strengthens the global environment for innovative medicines and brings much-needed equity to American-British medicine commerce," an announcement said.
Trade Significance
Drugs represent one of the UK's most significant exports to the America, which is easily the biggest destination for leading companies like GSK and AstraZeneca.
Trade data show that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products worth billions to the US. This figure accounted for 17.4% of total UK exports in that period.
"This agreement safeguards employment, stimulates capital expenditure and facilitates the UK to become a international leader for medical research," a minister remarked.
Detailed British Pledges
The pact involves several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum drug companies must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds topped 20%.
Recent Tensions
This agreement follows a long-running tension between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were exacerbated by claims that US patients were paying several times more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or cancelled, while major expansions have been announced toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a percentage of its resources over the previous ten-year period.
